(Dan Tri) – These three drugs were selected by an independent panel of experts and will be clinically tested in 52 countries.

Caring for Covid-19 patients at a hospital in the US (Illustration photo: Reuters).

Reuters said that three drugs, including Artesunate, Imatinib and Infliximab, were tested as part of the next phase of the Solidarity program (also known as Solidarity PLUS) led by WHO to find a treatment drug to reduce the risk of death.

Artesunate has been used in the treatment of severe malaria, while Imatinib is used to treat certain cancers, and Infliximab is used for diseases related to the immune system such as rheumatoid arthritis.

WHO said that within the framework of the clinical trial, the drug Artesunate will be injected into the patient’s veins for 7 consecutive days, at the standard recommended dose similar to the treatment of severe malaria.

WHO Director-General Tedros Adhanom Ghebreyesus emphasized: `Finding more effective, more accessible therapies for Covid-19 patients remains an urgent need and WHO is proud to lead this global effort

Solidarity PLUS involves thousands of researchers at more than 600 hospitals in 52 countries.

This allows testing and evaluating multiple treatments at the same time with the participation of thousands of Covid-19 patients.

Previously, also within the framework of the Solidarity trial program last year, 4 drugs including Remdesivir, Hydroxychloroquine, Lopinavir/Ritonavir and Interferon were tested with more than 13,000 patients in 500 hospitals in 30 different countries.

Countries around the world are trying to find different measures to stop and deal with the Covid-19 pandemic.

There is currently no specific medicine for people with Covid-19, however, the US Food and Drug Administration (FDA) has licensed three types of treatment medicine.

The Covid-19 epidemic started in December 2019 and has so far infected nearly 204 million people, of whom at least 4.3 million have died.